TGFB1 and systemic sclerosis: Emerging evidence positions metformin (Met) as a potent TGF-β inhibitor with validated antifibrotic effects in both SSc and diabetic nephropathy models and it has anti-inflammatory and angiogenesis-promoting effects [27,28,29].